Transcriptomic and single-cell analyses reveal the prognostic value of ETV4 and its role in shaping the immune landscape of colorectal cancer
Ruipeng Meng, Shilong Wang, Zhanfei She, Huaiming Wang, Bo Wu, Yu Qiao, Pengyuan Chen, Nargerel, Xiaofeng Yang, Liang Wang · 2026
Read Transcriptomic and single-cell analyses reveal the prognostic value of ETV4 and its role in shaping the immune landscape of colorectal cancer by Ruipeng Meng, Shilong Wang, Zhanfei She, Huaiming Wang, Bo Wu, Yu Qiao, Pengyuan Chen, Nargerel, Xiaofeng Yang, Liang Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13101611.txt.
Description
Ruipeng Meng and nine co-authors wrote this 2026 study on a transcription factor that marks, and may help drive, aggressive colorectal cancer. ETV4 had been implicated in several cancers, but its role in bowel tumors and their immune surroundings was unsettled. The team combined atlas-scale gene data, single-cell sequencing, and lab validation on patient tissue and a cancer cell line.
ETV4 ran high in tumors and tracked with shorter survival. Tumors rich in it also harbored more M2 macrophages, the immunosuppressive kind that shields cancers from attack. Experiments tied the factor to a famous growth pathway, WNT, which switches ETV4 on; blocking the pathway switched it down. The authors propose ETV4 as both a prognostic biomarker and a candidate drug target, arguing it helps build the protective immune fog around the tumor.
Catalog record
| CREATOR | Ruipeng Meng, Shilong Wang, Zhanfei She, Huaiming Wang, Bo Wu, Yu Qiao, Pengyuan Chen, Nargerel, Xiaofeng Yang, Liang Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |